Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL)

Pedro Engel Gonzalez; Mark A. Hlatky; Jo Ann E. Manson; Julie E. Buring; I. Min Lee; Nancy R. Cook; Vadim Bubes; Neil J. Stone

doi:10.1016/j.ahj.2022.06.001

Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL)

Pedro Engel Gonzalez, Mark A. Hlatky^*, Jo Ann E. Manson, Julie E. Buring, I. Min Lee, Nancy R. Cook, Vadim Bubes, Neil J. Stone

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

Statins are highly effective medications that reduce risk of atherosclerotic cardiovascular disease, but are very commonly discontinued by patients because of muscle symptoms. The risk factors for statin-associated muscle symptoms (SAMS) are not well understood, so in this study we examined the predictors of SAMS in a well-studied cohort of patients in the VITAL trial. We found that female sex and younger age (50-64 years) were significant, independent predictors of higher rates of SAMS.

Original language	English (US)
Pages (from-to)	39-41
Number of pages	3
Journal	American heart journal
Volume	252
DOIs	https://doi.org/10.1016/j.ahj.2022.06.001
State	Published - Oct 2022

Funding

This study was supported by the Hyperlipidemia Research Fund at Northwestern University. The VITAL trial was supported by grants (R01 AT011729, U01 CA138962, and R01 CA138962) from the National Institutes of Health. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents. The authors have no relationships with industry to declare.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ahj.2022.06.001

Cite this

@article{43516ebaf23b42b3ab6eefc81c74493d,

title = "Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL)",

abstract = "Statins are highly effective medications that reduce risk of atherosclerotic cardiovascular disease, but are very commonly discontinued by patients because of muscle symptoms. The risk factors for statin-associated muscle symptoms (SAMS) are not well understood, so in this study we examined the predictors of SAMS in a well-studied cohort of patients in the VITAL trial. We found that female sex and younger age (50-64 years) were significant, independent predictors of higher rates of SAMS.",

author = "Gonzalez, {Pedro Engel} and Hlatky, {Mark A.} and Manson, {Jo Ann E.} and Buring, {Julie E.} and Lee, {I. Min} and Cook, {Nancy R.} and Vadim Bubes and Stone, {Neil J.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = oct,

doi = "10.1016/j.ahj.2022.06.001",

language = "English (US)",

volume = "252",

pages = "39--41",

journal = "American heart journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL)

AU - Gonzalez, Pedro Engel

AU - Hlatky, Mark A.

AU - Manson, Jo Ann E.

AU - Buring, Julie E.

AU - Lee, I. Min

AU - Cook, Nancy R.

AU - Bubes, Vadim

AU - Stone, Neil J.

PY - 2022/10

Y1 - 2022/10

N2 - Statins are highly effective medications that reduce risk of atherosclerotic cardiovascular disease, but are very commonly discontinued by patients because of muscle symptoms. The risk factors for statin-associated muscle symptoms (SAMS) are not well understood, so in this study we examined the predictors of SAMS in a well-studied cohort of patients in the VITAL trial. We found that female sex and younger age (50-64 years) were significant, independent predictors of higher rates of SAMS.

AB - Statins are highly effective medications that reduce risk of atherosclerotic cardiovascular disease, but are very commonly discontinued by patients because of muscle symptoms. The risk factors for statin-associated muscle symptoms (SAMS) are not well understood, so in this study we examined the predictors of SAMS in a well-studied cohort of patients in the VITAL trial. We found that female sex and younger age (50-64 years) were significant, independent predictors of higher rates of SAMS.

UR - http://www.scopus.com/inward/record.url?scp=85133441792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133441792&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2022.06.001

DO - 10.1016/j.ahj.2022.06.001

M3 - Letter

C2 - 35717999

AN - SCOPUS:85133441792

SN - 0002-8703

VL - 252

SP - 39

EP - 41

JO - American heart journal

JF - American heart journal

ER -

Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL)

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this